PR Web12.09.20
Captiva Spine Inc., developer and distributor of intuitive spine fusion devices, has received a “Notice of Allowance” by the United States Patent and Trademark Office (USPTO) for its patent on a novel posterior sacroiliac (SI) joint fusion System named TransFasten. Specifically, the system’s precision form of Quadracentric carpentry which prepares the sacroiliac joint intended for an easy, safe, and repeatable SI joint fusion surgery.
“Recognizing the growing adoption of SI fusion procedures, we are committed to the continued development of differentiated and proprietary devices that clearly provide incremental improvement. This patent marks another milestone for Captiva Spine’s growing patent portfolio,” said Dale Mitchell, president of Captiva Spine. “TransFasten’s form of carpentry is truly aligned with key principles of achieving ease of use, stabilization, and fusion while utilizing a safe posterior approach.”
The TransFasten technique is intended to provide stabilization of the SI joint, with minimal disruption to anatomy, in a minimally invasive procedure. This patented Quadracentric site preparation is a form of mortise and tenon carpentry and requires one implant; many other systems require multiple implants or large screws. TransFasten is a precision-machined allograft with a large graft window that precisely fits within the sizeable cross-joint decortication for creating a biologic fusion.
This posterior procedure provides a safe approach to dock minimal instrumentation. It prepares the SI joint site which includes the richest proliferation of osteogenic cells while placing the implant in a predetermined position. Altogether, TransFasten may potentially reduce operating room and fluoroscopy time.
“As Captiva Spine continues to introduce TransFasten, many will bring this procedure to their practice simply for the safety of the posterior approach coupled with this unique approach to SI joint fusion site preparation,” said Dr. Robert E. Lins, The Center for the Bone & Joint Surgery, and inventor of TransFasten. “Because the sacroiliac joints transfer forces from the upper body to the lower extremities, they are subject to trauma and chronic degenerative changes. I truly believe the TransFasten procedure will enable the medical community to better serve their patients suffering these degenerative changes in the future.”
“Recognizing the growing adoption of SI fusion procedures, we are committed to the continued development of differentiated and proprietary devices that clearly provide incremental improvement. This patent marks another milestone for Captiva Spine’s growing patent portfolio,” said Dale Mitchell, president of Captiva Spine. “TransFasten’s form of carpentry is truly aligned with key principles of achieving ease of use, stabilization, and fusion while utilizing a safe posterior approach.”
The TransFasten technique is intended to provide stabilization of the SI joint, with minimal disruption to anatomy, in a minimally invasive procedure. This patented Quadracentric site preparation is a form of mortise and tenon carpentry and requires one implant; many other systems require multiple implants or large screws. TransFasten is a precision-machined allograft with a large graft window that precisely fits within the sizeable cross-joint decortication for creating a biologic fusion.
This posterior procedure provides a safe approach to dock minimal instrumentation. It prepares the SI joint site which includes the richest proliferation of osteogenic cells while placing the implant in a predetermined position. Altogether, TransFasten may potentially reduce operating room and fluoroscopy time.
“As Captiva Spine continues to introduce TransFasten, many will bring this procedure to their practice simply for the safety of the posterior approach coupled with this unique approach to SI joint fusion site preparation,” said Dr. Robert E. Lins, The Center for the Bone & Joint Surgery, and inventor of TransFasten. “Because the sacroiliac joints transfer forces from the upper body to the lower extremities, they are subject to trauma and chronic degenerative changes. I truly believe the TransFasten procedure will enable the medical community to better serve their patients suffering these degenerative changes in the future.”